IN THE SPOTLIGHT

In silico design of a multi-epitope vaccine against NSCLC targeting T-cell exhaustion and metastasis: insights from RNA-seq and molecular dynamics simulation analysis

In silico design of a multi-epitope vaccine against NSCLC targeting T-cell exhaustion and metastasis: insights from RNA-seq and molecular dynamics simulation analysis

Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

Stephen V Liu: Results from the CORRELATE Study Show Shorter Real-World OS and PFS Compared With Clinical Trials in NSCLC

Stephen V Liu: Results from the CORRELATE Study Show Shorter Real-World OS and PFS Compared With Clinical Trials in NSCLC

Editorial: Biomarker-guided strategies in NSCLC immunotherapy

Editorial: Biomarker-guided strategies in NSCLC immunotherapy

Phase 3 Trial of Calderasib Combo Launched in Advanced KRAS G12C-Mutant NSCLC

Phase 3 Trial of Calderasib Combo Launched in Advanced KRAS G12C-Mutant NSCLC

MSD begins KANDLELIT-007 trial of calderasib for NSCLC

MSD begins KANDLELIT-007 trial of calderasib for NSCLC

Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis

Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis